Albuterol

Albuterol

SCHEMBL3635442

CC(C)(C)NCC(O)c1ccc(O)c(CO)c1.CC(C)(C)NCC(O)c1ccc(O)c(CO)c1.CC(C)(C)NCC(O)c1ccc(O)c(CO)c1.O=S(=O)(O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB2

The experimentally established mechanism targets of Albuterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADRB2 known ✓ P07550 9/20 0.87
PMP22 Q01453 1/20 1.00
HIF1A Q16665 2/20 0.87
ADRB1 P08588 2/20 0.87
CYP1A2 P05177 1/20 0.87
CYP2D6 P10635 1/20 0.87
TSHR P16473 1/20 0.87
NFKB1 P19838 1/20 0.87
TDP1 Q9NUW8 1/20 0.85
KDM4E B2RXH2 1/20 0.60
CASP1 P29466 1/20 0.60
CASP7 P55210 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
MEN1 O00255 1/20 0.60
LMNA P02545 1/20 0.60
BLM P54132 1/20 0.60
KMT2A Q03164 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Albuterol SCHEMBL33280 1.00 PMP22 (1.00) PMP22ADRB2HIF1AADRB1CYP1A2
Albuterol SCHEMBL29372778 1.00 PMP22 (1.00) PMP22ADRB2HIF1AADRB1CYP1A2
Albuterol SCHEMBL33279 1.00 PMP22 (1.00) PMP22ADRB2HIF1AADRB1CYP1A2
Levosalbutamol SCHEMBL29568212 1.00 PMP22 (1.00) PMP22ADRB2HIF1AADRB1CYP1A2
Albuterol SCHEMBL6861017 1.00 PMP22 (1.00) PMP22ADRB2HIF1AADRB1CYP1A2
Levosalbutamol SCHEMBL33281 1.00 PMP22 (1.00) PMP22ADRB2HIF1AADRB1CYP1A2
Albuterol SCHEMBL2405201 1.00 PMP22 (1.00) PMP22ADRB2HIF1AADRB1CYP1A2
Albuterol SCHEMBL2556890 1.00 PMP22 (1.00) PMP22ADRB2HIF1AADRB1CYP1A2
Albuterol SCHEMBL15995296 0.99 PMP22 (0.97) PMP22ADRB2HIF1AADRB1CYP1A2
Albuterol SCHEMBL5472402 0.99 PMP22 (0.97) PMP22ADRB2HIF1AADRB1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140330587-A1 MEDICAL DIAGNOSIS DERIVED FROM PATIENT DRUG HISTORY DATA 3M INNOVATIVE PROPERTIES COMPANY 2014-11-06 US disclosed
US-8814790-B2 Medical diagnosis derived from patient drug history data 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-08-26 US disclosed
US-8579811-B2 Medical diagnosis derived from patient drug history data 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-11-12 US disclosed
US-20130226618-A1 MEDICAL DIAGNOSIS DERIVED FROM PATIENT DRUG HISTORY DATA 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-08-29 US disclosed
EP-2148663-A2 PULMONARY DELIVERY OF SPHERICAL INSULIN MICROPARTICLES Baxter International Inc. (US) 2010-02-03 EP disclosed
EP-2034883-A2 MEDICAL DIAGNOSIS DERIVED FROM PATIENT DRUG HISTORY DATA 3M Innovative Properties Company (US) 2009-03-18 EP disclosed
WO-2008130803-A2 PULMONARY DELIVERY OF SPHERICAL INSULIN MICROPARTICLES BAXTER INTERNATIONAL INC. (US) 2008-10-30 WO disclosed
EP-1944016-A1 Propellant-based microparticle formulatons BAXTER INTERNATIONAL INC. (US) 2008-07-16 EP disclosed
EP-1418890-B1 PROPELLANT-BASED MICROPARTICLE FORMULATIONS BAXTER INT (US) 2008-05-14 EP disclosed
US-20080081955-A1 MEDICAL DIAGNOSIS DERIVED FROM PATIENT DRUG HISTORY DATA 3M INNOVATIVE PROPERTIES COMPANY 2008-04-03 US disclosed
US-20080026068-A1 PULMONARY DELIVERY OF SPHERICAL INSULIN MICROPARTICLES BAXTER HEALTHCARE S.A. (CH) 2008-01-31 US disclosed
WO-2007149675-A2 MEDICAL DIAGNOSIS DERIVED FROM PATIENT DRUG HISTORY DATA 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-12-27 WO disclosed
EP-1418890-A1 PROPELLANT-BASED MICROPARTICLE FORMULATIONS BAXTER INTERNATIONAL INC. (US) 2004-05-19 EP disclosed
US-20030064033-A1 Propellant-based microparticle formulations BAXTER HEALTHCARE SA (A CORPORATION OF SWITZERLAND) (CH) 2003-04-03 US disclosed
WO-2003015750-A1 PROPELLANT-BASED MICROPARTICLE FORMULATIONS BAXTER INTERNATIONAL, INC. (US) 2003-02-27 WO disclosed